USSN 10/799.784

CT-2775NP

Remarks

Status of the claims. Claims 1 and 4-12 are pending, Claims 2 and 3 were previously cancelled. Claim 13 has been withdrawn from consideration. Claims 1, 4-9, and 12 were rejected under 35 USC 112 for amended claims that were deemed to add matter not described in the specification. Claims 10 and 11 were objected to for being dependent on a rejected claim.

Amendments. The definitions of R² and R³ were amended to delete the terms the examiner deemed new matter. The applicants believe the claims are now allowable and respectfully request the examiner withdraw the rejection based on 35 USC 112. The applicants also believe that claims 10 and 11 now depend on allowable claims and respectfully request the examiner to withdraw the objections to these claims.

Rejoinder of withdrawn claim under MPEP 821.04. If claim 1 is now deemed allowable, the applicants request that claim 13 be rejoined as a related method of using an allowed product claim.

The applicants believe the application is now in allowable form and respectfully request favorable reconsideration. If any issues remain regarding the allowance of this application, the Examiner is respectfully invited to contact the applicants' agent, James Epperson, by phone (203-677-6974), fax (203-677-6900), or email (james.epperson@bms.com).

Respectfully submitted,

Bristol-Myers Squibb Company

Patent Department

Princeton, NJ 08543-4000

Agent for Applicants P.O. Box 4000 Reg. No. 52,867

Phone: (203) 677-6974

James Epperson